Therapy Areas: Vaccines
Appili Therapeutics Touts Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701
24 November 2021 - - Canadian biopharmaceutical company Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) has posted positive one year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia, the company said.

According to the data released, the survival rate of 29% (n = 2/7) was reported in the ATI-1701 vaccinated cohort, compared to 0% (n = 0/5) in mock vaccinated controls.

The results are from the final challenge timepoint in a preclinical study evaluating the efficacy of ATI-1701 28 days, 90 days, and one year after vaccination.

At each challenge timepoint, cohorts of vaccinated and unvaccinated animals received a lethal exposure of aerosolized Francisella tularensis, the causative agent of tularemia.

In January 2020, Appili had reported 90-day efficacy results, with 100% of ATI-1701 vaccinated animals surviving exposure compared to 0% of the controls.

Both 28- and 90-day efficacy data have also been presented previously by Appili's partners MRIGlobal at biodefense conferences in the US.

The study was funded by the U.S Defense Threat Reduction Agency and conducted by MRIGlobal.

The company also said that Josef Vejvoda has resigned from the company's board of directors to pursue other endeavours.

Appili is developing ATI-1701 as a vaccine to combat Francisella tularensis, which is classified by the US National Institutes of Health as a Category A pathogen, an organism that poses the highest risk to national security and public health.